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Influenza	infection	manifests	in	a	wide	spectrum	of	severity,	
including	symptomless	pathogen	carriers.	We	conducted	a	
systematic	 review	and	meta-analysis	 of	 55	 studies	 to	 elu-
cidate	 the	proportional	 representation	of	 these	asymptom-
atic	 infected	persons.	We	observed	extensive	heterogene-
ity	among	 these	studies.	The	prevalence	of	asymptomatic	
carriage	(total	absence	of	symptoms)	ranged	from	5.2%	to	
35.5%	and	subclinical	cases	(illness	that	did	not	meet	the	cri-
teria	for	acute	respiratory	or	influenza-like	illness)	from	25.4%	
to	61.8%.	Statistical	analysis	showed	that	the	heterogeneity	
could	not	be	explained	by	the	type	of	influenza,	the	labora-
tory	tests	used	to	detect	the	virus,	the	year	of	the	study,	or	
the	location	of	the	study.	Projections	of	infection	spread	and	
strategies	for	disease	control	require	that	we	identify	the	pro-
portional	 representation	of	 these	 insidious	spreaders	early	
on	 in	 the	emergence	of	new	 influenza	subtypes	or	strains	
and	track	how	this	rate	evolves	over	time	and	space.
Infection of the respiratory tract with an influenza virus results in symptoms ranging from mild nonfebrile illness 
to severe disease and complications, including pneumo-
nia, shock, renal failure, encephalopathy, and multiorgan 
dysfunction (1,2). Influenza viruses infect 5%–15% of the 
global population annually (3), accounting for ≈500,000 
deaths (4) and 19 million disability-adjusted life years (5). 
The occurrence of asymptomatic influenza viruses infec-
tions has been recognized for some time (6), but determi-
nations about their possible role in transmission are largely 
speculative (7,8). Clarifying the role of these infections in 
virus transmission requires a solid understanding of their 
rate of occurrence.
Interest in the contribution of asymptomatic infection 
to influenza virus transmission has risen in recent years 
after a series of outbreaks caused by newly emerging sub-
types (9–12). Subclinical infection eludes symptomatic sur-
veillance, and resulting illnesses thus manifest as sporadic 
disease. Social network analysis indicates that nearly one 
third of the attack rate for influenza A(H1N1)pdm09 virus 
in England was attributable to asymptomatic infection (13), 
a proportion mirrored by a recent review of volunteer chal-
lenge studies (14). Mathematical modeling studies designed 
to inform pandemic preparedness and vaccination thresh-
olds and stockpiling strategies have typically had to resort 
to using these types of indirect metrics for parameterization 
(15–17). Current policy surrounding intervention planning 
for pandemic and interpandemic influenza is informed by 
estimates and simulations that arbitrarily assume a constant 
rate of asymptomatic infection in the range of 30%–50%.
However, mortality rates, clinical symptoms, and 
basic reproduction numbers (outbreak thresholds) vary 
greatly between influenza virus types, subtypes, and strains 
(18). Therefore, assigning an arbitrary value for asymptom-
atic infection rates that does not reflect this heterogeneity 
presents an important shortcoming in the current ability to 
accurately predict influenza outbreaks. Therefore, we con-
ducted a systematic review and meta-analysis to determine 
the prevalence of asymptomatic influenza infection and to 
identify any factors associated with the heterogeneity re-
ported across studies.
Methods
Search Strategy and Selection Criteria
A systematic review and meta-analysis was conducted in 
accordance with PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines (19). 
Literature searches were performed on the PubMed and 
Web of Science databases for the period from the incep-
tion of these databases to the beginning of 2015 to identify 
studies that reported laboratory-confirmed influenza infec-
tion (i.e., by culture, PCR, or serologic testing) and the pro-
portion of symptomatic versus asymptomatic presentation. 
Search terms were chosen to ensure maximum coverage 
of possible literature and included the terms “influenza,” 
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“carrier,” “carriage,” “shedding,” “asymptomatic,” “influen-
za AND prophylaxis NOT vaccine” (filtered for randomized 
control trials), “influenza AND (travel OR migration OR im-
migra*) AND (screening OR test OR testing OR detection),” 
“subclinical,” “serosurvey OR seroprevalence OR seroepi-
demiology.” Other keywords and connectors were also used 
(online Technical Appendix 1, http://wwwnc.cdc.gov/EID/
article/22/6/15-1080-Techapp1.pdf).
To be eligible for inclusion, studies needed to 1) be 
peer-reviewed and 2) report the prevalence of asymptomat-
ic influenza virus infections in humans or present the appro-
priate data from which that prevalence could be calculated. 
Laboratory confirmation of influenza was a requirement, 
and it had to be possible to correlate these data to the num-
ber of symptomatic patients. We did not impose limitations 
in terms of study design, influenza virus type, or exposure 
type (community or experimental inoculation). According 
to current World Health Organization guidelines, laboratory 
confirmation consisted of 1) conventional PCR (referred to 
here as PCR) or real-time reverse transcription PCR (rRT-
PCR); 2) virus antigen detection by immunofluorescence or 
enzyme immunoassay methods; 3) serologic detection of 
antibodies (hemagglutination inhibition); or 4) virus culture 
(20). Studies were excluded when the use of antiviral agents 
without a placebo group was reported. In cases in which a 
placebo group was used and an asymptomatic proportion 
could be determined, only this subset was used; otherwise, 
the study was excluded. Results were restricted to studies 
published in English; however, no restriction was placed on 
the publication date of studies that fit these criteria.
Study Selection and Data Extraction
Two authors (L.F-K. and M.C.) independently screened 
the publications for eligibility in a stepwise fashion. Search 
results were initially screened based on article titles and 
abstracts. Then, full-text analysis was performed to identify 
all studies which either reported asymptomatic prevalence 
or from which asymptomatic prevalence could be calcu-
lated. Any discrepancies that might have affected inclusion 
or exclusion of a study were resolved through discussion 
and consensus after independent evaluation by another au-
thor (L.Y.). The same 2 authors (L.F-K. and M.C.) assessed 
the risk for bias of the studies included by using a modified 
version of the tool developed by Hoy et al. (21) for preva-
lence studies (online Technical Appendix 2, http://wwwnc.
cdc.gov/EID/article/22/6/15-1080-Techapp2.pdf).
The definitions of asymptomatic influenza infection 
varied considerably between studies. Definitions ranged 
from a total absence of symptoms to a lack of influenza-
like illness (ILI) or acute respiratory illness (ARI). For the 
sake of clarity, we used the term “asymptomatic” when 
there was a total absence of symptoms and “subclinical” 
when the patient did not meet the authors’ criteria for ILI 
or ARI. Asymptomatic influenza prevalence was consid-
ered to be the proportion of all persons with laboratory-
confirmed influenza who had no symptoms, whereas sub-
clinical influenza prevalence was the proportion of persons 
with laboratory-confirmed influenza who failed to meet the 
study’s definition of symptomatic infection. In addition to 
collecting data on asymptomatic and subclinical infection 
prevalence, we collected data on influenza virus type/sub-
type and study characteristics (e.g., study design, sample 
size, diagnostic test used to detect influenza virus infection, 
and the working definition of “symptomatic”).
Statistical Analysis
We used prevalence of asymptomatic versus subclinical 
carriers among persons with laboratory-confirmed influen-
za as primary endpoints of interest. We pooled the preva-
lence estimates of asymptomatic and subclinical influenza 
across studies by using 2 meta-analytical models, the in-
verse variance heterogeneity model (22) and the random 
effects model.
We observed considerable heterogeneity across stud-
ies. This heterogeneity was unlikely to be attributable only 
to random or systematic errors, and actual clinical heteroge-
neity was deemed to exist. Therefore, we created subgroups 
by influenza virus type/subtype with the aim of generating 
more homogeneous groups within which we could antici-
pate that the differences indeed reflected variability caused 
by random or systematic error rather than actual clinical het-
erogeneity. In addition, we built a linear model to examine 
the variance explained by the influenza virus type/subtype, 
laboratory test used to detect the virus, year of the study, 
and geographic location of the study to gain insight into 
the considerable heterogeneity observed in the prevalence 
of asymptomatic and subclinical infections. We conducted 
the meta-analyses by using MetaXL version 2.0 (EpiGear 
Int Pty Ltd, Brisbane, QLD, Australia), which also included 
the inverse variance heterogeneity method, and the general-
ized linear model by using Stata version 12 (StataCorp LP, 
College Station, TX, USA). All tests were 2-tailed, and a p 
value <0.05 was deemed statistically significant. 
Results
Yield of Search Strategy
A total of 13,219 records were identified from literature 
searches of the 2 databases. This number was reduced to 
9,900 after removal of publications that were either dupli-
cates or not original research papers (e.g., review papers). 
An additional 3,663 papers were removed based on the title 
and 5,652 papers more based on the abstract. The full texts 
of the remaining 585 studies were examined, and 55 ar-
ticles met the inclusion criteria and were included in the 
final analysis (Figure; online Technical Appendix 1).
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Characteristics of the Studies Included
The 55 articles provided 59 data points because 4 papers 
reported the prevalence of asymptomatic and subclinical 
carriers for influenza A and B viruses separately. Over-
all, 19 studies (22 data points) defined asymptomatic in-
fection as cases in persons lacking symptoms, and 44 
studies (46 data points) reported subclinical influenza 
virus infections.
Infection was confirmed by serologic testing, rRT-
PCR, or viral culture; 28 studies reported use of serologic 
testing alone to confirm infection, 18 used rRT-PCR alone, 
and the remaining 9 used a combination of methods (5 sero-
logic testing and rRT-PCR, 3 serologic testing and culture, 
and 1 rRT-PCR and culture). Among the 55 studies, in-
fluenza A virus (predominantly H1N1) was the most com-
mon type of infection; 5 studies reported influenza B virus 
infections, and 1 study reported influenza C infections (on-
line Technical Appendix 1 Table 2). Most studies reported 
on pandemic influenza virus types; 32 of these studies re-
lated to the 2009 pandemic influenza A/Mexico/4108/2009 
strain. The risk for bias was moderate in 32% of the studies 
and low in the remaining 68%; no study was found to have 
a high risk for bias.
Quantitative Synthesis
The overall pooled prevalence for asymptomatic carriers 
was 19.1% (95% CI 5.2%–35.5%) for any type of influenza, 
21.0% (95% CI 4.2%–41.0%) for influenza A, and 22.7% 
(95% CI 7.7%–39.8%) for influenza A(H1N1) (Table 1; 
online Technical Appendix 2 Figure 1). For subclinical 
carriers, the overall pooled prevalence was 43.4% (95% 
CI 25.4%–61.8%) for any type of influenza, 42.8% (95% 
CI 22.3%–63.9%) for influenza A, and 39.8% (95% CI 
16.4%–64.5%) for influenza A(H1N1) (Table 1; online 
Technical Appendix 2 Figure 2). However, extensive het-
erogeneity was immediately evident for reported asymp-
tomatic prevalence (τ2 = 0.31) and subclinical prevalence 
(τ2 = 0.45) that could not be explained by the influenza 
type/subtype alone. Similar results were obtained with 
the random effects model (online Technical Appendix 2 
Figures 3, 4).
Investigation of Heterogeneity
The considerable heterogeneity observed within asymp-
tomatic and subclinical influenza prevalence could not be 
explained by the type/subtype of influenza, the laboratory 
tests used to detect the virus, the location where the study 
was conducted, or the year of the study. The multivariate 
regression models could only explain 16.8% and 14.8% of 
the observed variance for the asymptomatic and subclini-
cal prevalence, respectively. Influenza type/subtype as an 
independent predictor was found to account for almost the 
entire variance (16%) found for the prevalence of asymp-
tomatic carriers (Table 2).
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Figure.	PRISMA	(Preferred	
Reporting	Items	for	Systematic	
Reviews	and	Meta-Analysis)	
flowchart	of	literature	search	 
for	systematic	review	and	 
meta-analysis	of	asymptomatic	
and	subclinical	influenza	
infection	prevalence.
 
 
 
Table 1. Heterogeneity	within	asymptomatic	and	subclinical	influenza	infection	cases,	by	virus	type/subtype,	as	determined	through	a	
systematic	review	and	meta-analysis	of	55	studies 
Type/subtype Prevalence	(95%	CI) Cochran’s Q p value (Cochran’s Q) I2,*	% 
Asymptomatic     
 All	types	of	influenza 19.1	(5.2–35.5) 752.40 <0.001 97 
 Influenza	A 21.0	(4.2–41.0) 692.94 <0.001 98 
 Influenza	A(H1N1) 22.7	(7.7–39.8) 561.14 <0.001 97 
Subclinical     
 All	types	of	influenza 43.4	(25.4–61.8) 1768.24 <0.001 97 
 Influenza	A 42.8	(22.3–63.9) 1689.78 <0.001 98 
 Influenza	A(H1N1) 39.8	(16.4–64.5) 1388.54 <0.001 98 
*The	I²	statistic	describes	the	percentage	of	variation	across	studies	that is	attributable	to	heterogeneity	rather	than	chance.  
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Publication Bias
For both asymptomatic and subclinical carrier prevalence, 
the funnel plots showed no indication of publication bias. 
This result was confirmed by Doi plots (data not shown). 
Discussion
Studies of laboratory-confirmed influenza typically do 
not include details of the symptomatic versus asymp-
tomatic rate of infection. Of the few that do include this 
information, ambiguity exists between definitions of as-
ymptomatic versus subclinical infections. This has per-
petuated the ubiquitous issue of absent denominators in 
documented influenza rates and has caused substantial 
aberrations in initial reports of newly emerging subtypes 
and strains (23). We propose that the term “asymptomat-
ic” be used exclusively to describe the complete absence 
of symptoms associated with influenza virus infection 
in patients with laboratory-confirmed cases. Given that 
reporting of this rate in the clinical literature would re-
quire little to no additional effort for most study designs, 
we also propose that the asymptomatic rate of laboratory 
test–positive persons be declared explicitly by public 
health bodies and researchers.
We found no evidence to support a fixed asymptomatic 
rate (or even an informative range) between or even within 
influenza virus subtypes. For example, the prevalence of 
asymptomatic influenza A(H1N1) virus ranged from 0% 
to 65%, resulting in an overall failure to explain the ex-
treme heterogeneity in this reported rate. Some alternative 
explanations for the extreme heterogeneity are plausible, 
one being that generally applicable biologic mechanisms 
underlie the asymptomatic rates of influenza virus infection 
and these have been missed (e.g., details of patient vaccina-
tion or infection history were not routinely described in the 
clinical studies and data on sex and age of patients were ex-
cluded). Alternatively, influenza viruses conferring asymp-
tomatic infection mutate so rapidly that a meaningful single 
per–influenza type rate simply does not exist. Employing 
sensitive diagnostic testing and standardized reporting of 
the asymptomatic rate of influenza virus infection would 
elucidate any underlying mechanisms or demonstrate any 
temporal changes in this rate.
This lack of a convenient asymptomatic rate poses a 
considerable obstacle to public health planning. Disease 
surveillance and control strategy is contingent on reliable 
estimates for the asymptomatic rate and the contribution 
that asymptomatic persons have on transmissibility. For 
example, a low asymptomatic rate improves the utility 
of passive (i.e., symptom-based) surveillance, whereas a 
higher asymptomatic rate might prompt presumptive travel 
restrictions to curb the spread of newly emerging subtypes 
and strains, especially if a high mortality rate is evident ear-
ly in the outbreak. Future analyses correlating asymptomat-
ic rates with mortality rates are also required; although one 
could easily speculate that influenza subtypes and strains 
eliciting high asymptomatic rates probably incur corre-
spondingly low mortality rates, no evidence supporting this 
assumption currently exists.
Our study clearly demonstrates the inappropriateness 
of a one-size-fits-all approach to mitigating the spread 
of human influenza viruses. As new subtypes and strains 
emerge, actively surveying infection status of local popula-
tions and tracking any changes in asymptomatic rates of 
infection should increasingly become a global health pri-
ority, possibly necessitating the provision of international 
resources and the deployment of dedicated rapid-response 
teams who are guided by standardized protocols.
This work was supported by an Endeavour Postgraduate Schol-
arship (no. 3781_2014), an Australia National University Higher 
Degree Scholarship, and a Fondo para la Innovación, Ciencia, y 
Tecnología Scholarship (no. 095-FINCyT-BDE-2014) to L.F.K. 
The salary for G.J.M. was provided through the National Health 
and Medical Research Council, Australia (grant no. 1002608). 
The funders had no role in the conduct of the research.
Mr. Furuya-Kanamori is an infectious disease epidemiologist. He 
is enrolled in a PhD program at the Australian National University 
where he uses modern quantitative methods to better understand 
risk factors associated with different infectious diseases.
References
  1. Taubenberger JK, Morens DM. The pathology of influenza virus 
infections. Annu Rev Pathol. 2008;3:499–522. http://dx.doi.org/ 
10.1146/annurev.pathmechdis.3.121806.154316
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	22,	No.	6,	June	2016	 1055
 
 
 
Table 2. Variance	attributable	to	predictors	in	univariate	and	multivariate	regression	models	for	asymptomatic	and	subclinical	influenza	
infection	prevalence,	by	study	characteristics,	as	determined	through	a	systematic	review	and	meta-analysis	of	55	studies 
Model/characteristic Asymptomatic Subclinical 
Univariate	model   
 Influenza	type/subtype 0.1599 0.0345 
 Laboratory	test	used	to	detect	influenza 0.0043 0.0546 
 Hemisphere	where	study	was	conducted 0.0001 0.0159 
 Continent	where	study	was	conducted 0.0045 0.0213 
 Decade	when	study	was	conducted * 0.0064 
Multivariate	model 0.1676† 0.1478‡ 
*Variance	not	reported	because	all	the	studies	were	from	the	same	decade. 
†Model adjusted for influenza type/subtype, laboratory test, and location (continent) of the study. 
‡Model adjusted for influenza type/subtype, laboratory test, location (continent) of the study, and decade when the study was conducted. 
 
RESEARCH
  2. Cox NJ, Subbarao K. Influenza. Lancet. 1999;354:1277–82.  
http://dx.doi.org/10.1016/S0140-6736(99)01241-6
  3. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK,  
Cheng P-Y, et al. Estimated global mortality associated with the 
first 12 months of 2009 pandemic influenza A H1N1 virus  
circulation: a modelling study. Lancet Infect Dis. 2012;12:687–95. 
http://dx.doi.org/10.1016/S1473-3099(12)70121-4
  4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, 
et al. Global and regional mortality from 235 causes of death for 20 
age groups in 1990 and 2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet. 2012;380:2095–128.  
http://dx.doi.org/10.1016/S0140-6736(12)61728-0
  5. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD,  
Michaud C, et al. Disability-adjusted life years (DALYs) for 291  
diseases and injuries in 21 regions, 1990–2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 
380:2197–223. http://dx.doi.org/10.1016/S0140-6736(12)61689-4
  6. Elder AG, O’Donnell B, McCruden EA, Symington IS,  
Carman WF. Incidence and recall of influenza in a cohort of 
Glasgow healthcare workers during the 1993–4 epidemic: results of 
serum testing and questionnaire. BMJ. 1996;313:1241–2.  
http://dx.doi.org/10.1136/bmj.313.7067.1241
  7. Mathews JD, McCaw CT, McVernon J, McBryde ES, McCaw JM. 
A biological model for influenza transmission: pandemic planning 
implications of asymptomatic infection and immunity. PLoS One. 
2007;2:e1220. http://dx.doi.org/10.1371/journal.pone.0001220
  8. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS. 
Antiviral effects on influenza viral transmission and pathogenicity:  
observations from household-based trials. Am J Epidemiol. 2007; 
165:212–21. http://dx.doi.org/10.1093/aje/kwj362
  9. Arden KE, Mackay IM. Avian influenza A (H7N9) virus: can it 
help us more objectively judge all respiratory viruses? J Clin Virol. 
2013;58:338–9. http://dx.doi.org/10.1016/j.jcv.2013.05.015
10. Le MQ, Horby P, Fox A, Nguyen HT, Le Nguyen HK, Hoang PM,  
et al. Subclinical avian influenza A(H5N1) virus infection in  
human, Vietnam. Emerg Infect Dis. 2013;19:1674–7.  
http://dx.doi.org/10.3201/eid1910.130730
11. Lo YC, Chen WC, Huang WT, Lin YC, Liu MC, Kuo HW, et al. 
Surveillance of avian influenza A(H7N9) virus infection in humans 
and detection of the first imported human case in Taiwan, 3 April to 
10 May 2013. Euro Surveill. 2013;18:20479.
12. Song R, Pang X, Yang P, Shu Y, Zhang Y, Wang Q, et al.  
Surveillance of the first case of human avian influenza A (H7N9) 
virus in Beijing, China. Infection. 2014;42:127–33.  
http://dx.doi.org/10.1007/s15010-013-0533-9
13. Van Kerckhove K, Hens N, Edmunds WJ, Eames KTD. The impact 
of illness on social networks: implications for transmission and 
control of influenza. Am J Epidemiol. 2013;178:1655–62.  
http://dx.doi.org/10.1093/aje/kwt196
14. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, 
Leach S, et al. Time lines of infection and disease in human 
influenza: a review of volunteer challenge studies. Am J Epidemiol. 
2008;167:775–85. http://dx.doi.org/10.1093/aje/kwm375
15. Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing 
pandemic influenza with antiviral agents. Am J Epidemiol. 
2004;159:623–33. http://dx.doi.org/10.1093/aje/kwh092
16. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation 
strategies for pandemic influenza in the United States. Proc Natl 
Acad Sci U S A. 2006;103:5935–40. http://dx.doi.org/10.1073/
pnas.0601266103
17. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, 
Burke DS. Strategies for mitigating an influenza pandemic. Nature. 
2006;442:448–52. http://dx.doi.org/10.1038/nature04795
18. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all 
pandemics. Emerg Infect Dis. 2006;12:15–22. http://dx.doi.org/ 
10.3201/eid1209.05-0979
19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P; PRISMA 
Group. Preferred reporting items for systematic reviews and  
meta-analyses: the PRISMA statement. PLoS Med. 
2009;6:e1000097. http://dx.doi.org/10.1371/journal.pmed.1000097
20. World Health Organization. WHO Global Epidemiological  
Surveillance Standards for Influenza. 2014 [cited January 2015]. 
http://www.who.int/entity/influenza/resources/documents/WHO_ 
Epidemiological_Influenza_Surveillance_Standards_2014.pdf?ua=1 
21. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al.  
Assessing risk of bias in prevalence studies: modification of an  
existing tool and evidence of interrater agreement. J Clin Epidemiol. 
2012;65:934–9. http://dx.doi.org/10.1016/j.jclinepi.2011.11.014
22. Doi SA, Barendregt JJ, Khan S, Thalib L, Williams GM. Advances 
in the meta-analysis of heterogeneous clinical trials I: The inverse 
variance heterogeneity model. Contemp Clin Trials. 2015;45(Pt 
A):130–8. http://dx.doi.org/10.1016/j.cct.2015.05.009
23. Lambert SB, Faux CE, Grant KA, Williams SH, Bletchly C,  
Catton MG, et al. Influenza surveillance in Australia: we need to do 
more than count. Med J Aust. 2010;193:43–5.
Address for correspondence: Laith Yakob, London School of Hygiene 
and Tropical Medicine, Department of Disease Control, Keppel St, 
London WC1E 7HT, UK; email: laith.yakob@lshtm.ac.uk
1056	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	22,	No.	6,	June	2016
 
featured monthly in
Etymology is concerned 
with the origin of words, 
how they’ve evolved over 
time, and changed in 
form and meaning as they were translated from one language to  
another. Every month, EID publishes a feature highlighting the  
etymology of a word 
from medicine or 
public health. http://wwwnc.cdc.gov/eid/articles/etymologia 
etymologia
